Eyenovia to end eye drug study, cut 50% of its workforce
Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.
Jim Cramer on AppLovin Corporation (APP): ‘612% On A Company That Really Isn’t All That Speculative’
We recently compiled a list of the Jim Cramer’s Best Performers List: Top 10 Stocks. In this article, we are going to take a ...
BioPharma Dive16h
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
BioPharma Dive19h
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR | MarketsandMarkets™
The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...